Cangliflozin impurities are substances that may be present in cangliflozin drug products, either as by-products of the manufacturing process or as degradation products resulting from storage or handling. These impurities may affect the safety and efficacy of the drug product, and their identification and quantification are essential for ensuring the quality of the product. Therefore, thorough characterization and control of cangliflozin impurities are critical to ensure patient safety and regulatory compliance.